PMID: 6402781Mar 1, 1983Paper

Botrocetin (venom coagglutinin): reaction with a broad spectrum of multimeric forms of factor VIII macromolecular complex

Proceedings of the National Academy of Sciences of the United States of America
K M BrinkhousR H Wagner

Abstract

Botrocetin, originally called venom coagglutinin, is a Bothrops factor that causes aggregation of blood platelets in the presence of the von Willebrand component of the factor VIII macromolecular complex. The complex consists of a series of multimers with a molecular weight of about 1-20 x 10(6). Ristocetin, another agent that causes platelet aggregation dependent on von Willebrand factor, reacts with only the higher molecular weight multimers. We report on the reactivity of botrocetin in relation to the multimeric structure of the factor VIII complex. Several plasmas or plasma fractions with abnormal distribution of the multimeric sizes were examined, including variant von Willebrand disease type IIA with lack of the higher molecular weight forms, commercial antihemophilic factor concentrates with a preponderance of lower molecular weight forms, cryoprecipitate-free plasma containing mainly the smaller multimers, and a chromatographic fraction of plasma containing only the highest molecular weight polymers. Factor VIII-related antigen content was adjusted to 25-100%. All of the preparations lacking the high molecular weight forms caused prompt platelet aggregation with botrocetin, but none of them caused aggregation in the ris...Continue Reading

References

Sep 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·M S ReadK M Brinkhous
May 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·K M BrinkhousM S Read
Jun 29, 1981·Biochimica Et Biophysica Acta·B A PerretE A Beck

❮ Previous
Next ❯

Citations

Jan 1, 1986·Toxicon : Official Journal of the International Society on Toxinology·C H OuyangT F Huang
Jan 1, 1990·Toxicon : Official Journal of the International Society on Toxinology·R M Kini, H J Evans
Jan 1, 1985·Pharmacology & Therapeutics·F Kornalík
Jan 1, 1997·Biorheology·K KonstantopoulosJ L Moake
Mar 27, 2003·Toxicon : Official Journal of the International Society on Toxinology·H C CastroR B Zingali
Jan 25, 2005·Nature Structural & Molecular Biology·Koichi FukudaThomas G Diacovo
Jan 22, 2005·Seminars in Hematology·Grazia Loredana Mendolicchio, Zaverio M Ruggeri
Nov 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·D A BellingerT R Griggs
Oct 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·I RabinowitzJ E Sadler
Feb 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·Y UsamiK Titani
Mar 31, 2010·Toxicon : Official Journal of the International Society on Toxinology·Kenneth J Clemetson
Apr 25, 2006·Blood Cells, Molecules & Diseases·Xiao-Yan DuYun Zhang
Jun 1, 2005·Toxicon : Official Journal of the International Society on Toxinology·Takashi Morita
Jun 1, 2005·Toxicon : Official Journal of the International Society on Toxinology·Aura S Kamiguti
Oct 29, 2011·Toxicon : Official Journal of the International Society on Toxinology·Ponthip Mekchay, Ponlapat Rojnuckarin
Jan 1, 1991·Platelets·C M Teng, T F Huang
Jan 1, 1991·Critical Reviews in Toxicology·J Meier, K Stocker
Feb 1, 1985·American Journal of Hematology·H TakahashiA Shibata
Aug 28, 2020·Frontiers in Pharmacology·Karla de Castro Figueiredo BordonEliane Candiani Arantes
Oct 2, 2019·Frontiers in Immunology·Catarina TeixeiraAna Marisa Chudzinski-Tavassi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.